Von Willebrand factor assay profi ciency testing continued

American Journal of Clinical Pathology

Volumn 136, Issue 4, 2011, Pages 657-659

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB; RISTOCETIN; VON WILLEBRAND FACTOR;

FREEZE DRYING; HUMAN; IMMUNOASSAY; LABORATORY TEST; LETTER; PH; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

BLOOD COAGULATION TESTS; HUMANS; PROFESSIONAL COMPETENCE; VON WILLEBRAND FACTOR;

EID: 80053544296     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP65JXEHSJDHUR     Document Type: Letter

References (12)

1. Chandler WL, Peerschke EIB, Castellone DD, et al; on behalf of the NASCOLA Proficiency Testing Committee. von Willebrand factor assay proficiency testing: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol. 2011;135:862-869.
2. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European Concerted Action on Thrombosis and Disabilities Foundation. Semin Thromb Hemost. 2006;32:485-491. (Pubitemid 44157386)
3. Kitchen S, Jennings I, Woods TA, et al. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2006;32:492-498. (Pubitemid 44157387)
4. Favaloro EJ, Bonar R, Kershaw G, et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost. 2006;32:505-513. (Pubitemid 44157389)
5. Favaloro EJ, Smith J, Petinos P, et al; on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost. 1999;82:1276-1282. (Pubitemid 29473792)
6. Favaloro EJ, Smith J, Petinos P, et al; on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing, diagnosis and management of von Willebrand's disease: current practice in Australasia. Am J Clin Pathol. 1999;112:712-719. (Pubitemid 30214762)
7. Favaloro EJ, Bonar R, Marsden K; on behalf of the RCPA QAP Haemostasis Committee. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci. 2008;21:178-185.
8. Hillarp A, Stadler M, Haderer C, et al. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost. 2010;8:2216-2223.
9. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost. 2010;8:2842-2844.
10. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost. 2010;104:1009-1021.
11. Favaloro EJ. Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country? Pathology. 2011;43:397-402.
12. Favaloro EJ, Plebani M, Lippi G. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing? Clin Chem Lab Med. In press.